Biomm Projects 3,000% Growth in Ebitda After Disengagement from Banco Master

The Brazilian pharmaceutical company Biomm surprised the financial market by announcing, in a relevant fact published at the end of a Tuesday afternoon, extremely optimistic projections for the fiscal year of 2024. The company, the only national producer of glargine insulin — a human insulin analogue widely used in diabetes treatment —, expects an impressive 3,000% growth in its Ebitda (Earnings Before Interest, Taxes, Depreciation and Amortization).

The announcement comes at a strategic time: just two months after the company managed to officially detach itself from the controversial Banco Master scandal, one of the most talked-about episodes in the Brazilian financial market in recent times. The exit from this predicament was made possible by the entry of Alaska Asset Management into Biomm's shareholding structure, a move that brought not only new capital but also credibility and institutional support to the company.

---

What Is Biomm and Why Does It Matter?

Founded with the purpose of democratizing access to biological medications in Brazil, Biomm occupies a unique position in the national pharmaceutical ecosystem. Being the only Brazilian manufacturer of glargine insulin gives the company a competitive advantage that is difficult to replicate in the short term.

Glargine insulin is classified as a long-acting insulin analogue, and is widely prescribed for patients with type 1 and type 2 diabetes. In Brazil, where the number of diabetics exceeds 16 million people, according to data from the International Diabetes Federation, the demand for this type of medication is growing and structural.

Unlike conventional insulins, analogues like glargine offer more stable glycemic control with a lower risk of hypoglycemia. Until recently, the Brazilian market was almost entirely dominated by imported versions, making Biomm's product strategic both from a clinical perspective and a national pharmaceutical sovereignty standpoint.

---

The Banco Master Scandal and Its Impacts on Biomm

To understand the magnitude of the recovery projected by Biomm, it is necessary to contextualize the turbulent period the company went through. The Banco Master was at the center of a series of regulatory and governance questions that shook investor confidence in companies associated with the bank.

Biomm's association with this context generated:

• Loss of investor confidence and pressure on the company's shares;
• Challenges in raising funds for operational expansion;
• Noise in the company's institutional narrative, harming strategic partnerships;
• Increased volatility in the shares traded on the stock exchange.

The situation called for a quick and strong response from Biomm's leadership. The solution found was to seek a new strategic partner capable of conveying solidity to the market.

---

The Entry of Alaska Asset Management: A Turning Point

Alaska Asset Management, a firm with a recognized reputation in the Brazilian financial market and known for its positions in companies with high appreciation potential, decided to invest in Biomm at a moment of fragility — and this move appears to be proving wise.

Alaska's entry into the shareholding structure brought with it:

• New capital injection, essential to finance the expansion of production capacity;
• Positive signaling to the market, acting as a quality seal for other investors;
• Support in the financial structuring of the company, focusing on operational efficiency;
• Strengthening of corporate governance, a fundamental aspect after the fallout with Banco Master.

Firms of Alaska's stature rarely enter companies without a robust due diligence process. Therefore, its presence functions as a testament that Biomm's fundamentals are solid and that the growth potential is real.

---

The Numbers Behind the 3,000% Projection

A projected growth of 3,000% in Ebitda seems almost improbable at first glance, but can be understood when analyzing the company’s starting point. Companies that go through periods of financial and operational pressure often present very compressed or even negative Ebitda, which mathematically amplifies any recovery in percentage terms.

Among the factors supporting this projection are:

1. Increase in production capacity with the new funds raised;
2. Expansion of glargine insulin sales to the public and private sectors;
3. Reduction in operational costs through efficiencies implemented by the new management;
4. Growth in the market for insulin analogues in Brazil, fueled by changes in the SUS clinical protocols;
5. Possibility of new contracts with the Ministry of Health, given the government's interest in domestically produced pharmaceuticals.

---

The Insulin Market in Brazil: A Billion-Dollar Opportunity

The Brazilian insulin market generates billions of reais annually. With the rise of diabetes as a public health problem — driven by sedentary lifestyles, obesity, and an aging population — demand for insulins, especially long-acting analogues, is expected to grow steadily in the coming decades.

The federal government has shown increasing interest in nationalizing the production of strategic medications, especially after the lessons learned during the Covid-19 pandemic. Biomm, as the only national producer of glargine insulin, is strategically positioned to capture large government contracts.

---

Perspectives and Challenges Ahead

Despite the optimism, Biomm still faces significant challenges:

• Scalability of production without compromising the quality of the biological product;
• Competition from international giants like Novo Nordisk, Sanofi, and Eli Lilly;
• Need for regulatory approvals for new products in the pipeline;
• Maintaining investor confidence after the period of instability.

However, the current scenario is undeniably more favorable than it was six months ago. The combination of solid fundamentals, a unique market position, and new institutional support from Alaska creates the conditions for Biomm to effectively deliver part of the promised growth.

---

Conclusion: A Turnaround That the Market Is Watching Closely

Biomm's recent trajectory is, in many ways, a case study in business resilience and strategic repositioning. Transitioning from a reputation crisis linked to Banco Master to a projected 3,000% growth in Ebitda in just a few months is an achievement that few analysts would have predicted.

The next chapter of this story will be written in the quarterly results the company publishes throughout 2024. The financial market, Alaska investors, and the millions of Brazilian diabetic patients who depend on accessible insulin will be attentive to what Biomm has to deliver.

If the projections are confirmed, the Minas Gerais-based pharmaceutical company could become one of the most remarkable recovery cases on the Brazilian stock market in recent years — and a symbol of Brazil's ability to produce cutting-edge biotechnology on national soil.